What Genmab A/S (GMAB) Said on Its Q3 Earnings Call
Nov 5, 3:15 PM·
Medium Optimistic
Tickers
Summary
Genmab A/S (GMAB) reported 22% revenue growth for the first nine months of 2026, driven by EPKINLY sales and royalty income. Management said it expects full-year revenue to land in the upper part of its existing guidance range. The company discussed these results on its Q3 2026 earnings call, held on November 5, 2026.
Genmab Reports 22% Revenue Growth for First Nine Months of 2026
Genmab A/S (GMAB) reported 22% revenue growth for the first nine months of 2026, according to the company’s third-quarter earnings call held on November 5, 2026.
Growth Drivers
The revenue increase was driven by EPKINLY sales and royalty income, the company said on the call.
Full-Year Outlook
Management said it expects full-year revenue to land in the upper part of its existing guidance range.
Call Details
- Company: Genmab A/S (ticker: GMAB)
- Event: Q3 2026 earnings call
- Date: November 5, 2026
The earnings call transcript was published by Seeking Alpha.